Overview

Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

Status:
Recruiting

Trial end date:
2025-08-31

Target enrollment:

Participant gender:

Summary

In this study, patients with recurrent or metastatic head and neck squamous cell carcinoma will receive first line treatment with olaparib, pembrolizumab, and carboplatin. The primary hypothesis is that olaparib, pembrolizumab and carboplatin will result in an overall response rate (ORR) higher than the historical ORR observed with pembrolizumab, platinum and 5-FU.

Phase:

Phase 2

Details

Lead Sponsor:

Washington University School of Medicine

Collaborators:

Joseph Sanchez Foundation
Merck Sharp & Dohme Corp.

Treatments:

Carboplatin
Olaparib
Pembrolizumab